Information Provided By:
Fly News Breaks for September 18, 2017
JAZZ
Sep 18, 2017 | 07:43 EDT
JPMorgan analyst Jessica Fye raised her price target for Jazz Pharmaceuticals to $190 after her firm's 26 physician survey indicated a positive outlook for Vyxeos. Physicians in the survey expect Vyxeos will be the standard-of-care in acute myeloid leukemia with myelodysplasia-related changes over time, Fye tells investors in a research note. The analyst expects the drug to "meaningfully contribute" to Jazz's topline growth. She keeps an Overweight rating on the shares.
News For JAZZ From the Last 2 Days
There are no results for your query JAZZ